Alternative therapy against CTX-M broad spectrum β-lactamase resistance gene in Klebsiella pneumoniae infection: bee venom and bee venom-derived nanovesicle fraction

ArticleAçık Erişim

Özet

Antibiotic resistance is one of the most important problems threatening global public health by complicating the treatment of infections worldwide. The increase in resistant microorganisms creates a serious economic and social burden on healthcare systems and increasingly limits treatment options. Conscious use of antibiotics, infection control measures and the development of alternative treatment strategies are vital to ensure sustainability in health. Klebsiella pneumoniae is the most common gram-negative bacterium among urinary tract infections. Treatment of infections has become difficult due to the resistance to beta-lactam antibiotics. Bee venom (BV) and nanovesicle fractions isolated from BV are bioactive compounds with antimicrobial and antibiofilm activity. The aim of this study was to determine the antimicrobial and antibiofilm effects of BVand bee venom-derived nanovesicle fractions against the nosocomial infection agent K. pneumoniae, and to evaluate CTX-M PCR band detection under the tested conditions. Minimum inhibitory concentration (MIC), antibiofilm activity, fractional inhibition concentrations (FIC), CTX-M PCR band detection, and viability rates in L929 cells were evaluated for both BVand the bee venom-derived nanovesicle fraction against K. pneumoniae. MIC value of nanovesicle fractions isolated from BVwas determined as 1.95 mg/L. In combination with piperacillin and tazobactam, a synergistic effect was detected with a value of 0.5. Antibiofilm activity was measured with the highest absorbance value of 0.163 and 0.094 for BV nanovesicle fractions. A detectable CTX-M PCR band was observed in the BVgroup at 0.5× MIC, whereas no detectable band was observed at both concentrations by day 4. In the bee venom-derived nanovesicle fraction group, no detectable CTX-M PCR band was observed at 2× MIC and 0.5× MIC under the tested conditions. In contrast, detectable CTX-M PCR bands were observed in the piperacillin-tazobactam group. It was reported that the combination groups decreased the viability rate in L929 cell lines. The bee venom-derived nanovesicle fraction showed antimicrobial, antibiofilm, and PCR-based detection findings under the tested conditions, supporting the need for further investigation in broader in vitro and in vivo models. © The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia 2026.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10504Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s42770-026-02005-8Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCelebi, Demet
dc.contributor.authorCelebi, Ozgur
dc.contributor.authorBaser, Sumeyye
dc.contributor.authorTaghizadehghalehjoughi, Ali
dc.contributor.authorDabanlıoglu, Bulent
dc.contributor.authorGuler, Mustafa Can
dc.contributor.authorAydın, Elif
dc.contributor.authorYıldırım, Serkan
dc.date.accessioned2026-10-18T20:25:42.647315715Z
dc.date.available2026-10-18T20:25:42.647315715Z
dc.date.issued2026
dc.description.abstractAntibiotic resistance is one of the most important problems threatening global public health by complicating the treatment of infections worldwide. The increase in resistant microorganisms creates a serious economic and social burden on healthcare systems and increasingly limits treatment options. Conscious use of antibiotics, infection control measures and the development of alternative treatment strategies are vital to ensure sustainability in health. Klebsiella pneumoniae is the most common gram-negative bacterium among urinary tract infections. Treatment of infections has become difficult due to the resistance to beta-lactam antibiotics. Bee venom (BV) and nanovesicle fractions isolated from BV are bioactive compounds with antimicrobial and antibiofilm activity. The aim of this study was to determine the antimicrobial and antibiofilm effects of BVand bee venom-derived nanovesicle fractions against the nosocomial infection agent K. pneumoniae, and to evaluate CTX-M PCR band detection under the tested conditions. Minimum inhibitory concentration (MIC), antibiofilm activity, fractional inhibition concentrations (FIC), CTX-M PCR band detection, and viability rates in L929 cells were evaluated for both BVand the bee venom-derived nanovesicle fraction against K. pneumoniae. MIC value of nanovesicle fractions isolated from BVwas determined as 1.95 mg/L. In combination with piperacillin and tazobactam, a synergistic effect was detected with a value of 0.5. Antibiofilm activity was measured with the highest absorbance value of 0.163 and 0.094 for BV nanovesicle fractions. A detectable CTX-M PCR band was observed in the BVgroup at 0.5× MIC, whereas no detectable band was observed at both concentrations by day 4. In the bee venom-derived nanovesicle fraction group, no detectable CTX-M PCR band was observed at 2× MIC and 0.5× MIC under the tested conditions. In contrast, detectable CTX-M PCR bands were observed in the piperacillin-tazobactam group. It was reported that the combination groups decreased the viability rate in L929 cell lines. The bee venom-derived nanovesicle fraction showed antimicrobial, antibiofilm, and PCR-based detection findings under the tested conditions, supporting the need for further investigation in broader in vitro and in vivo models. © The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia 2026.
dc.description.sponsorshipThe authors declared that this study has received no financial support.
dc.identifier.doi10.1007/s42770-026-02005-8
dc.identifier.eissn1678-4405
dc.identifier.issn1517-8382
dc.identifier.issue1
dc.identifier.pmcidPMC13337971
dc.identifier.pmid42406012
dc.identifier.scopus2-s2.0-105044005163
dc.identifier.startpage192
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10504
dc.identifier.volume57
dc.identifier.wosWOS:001813378700004
dc.language.isoen
dc.publisherSpringer Nature
dc.relation.ispartofBrazilian Journal of Microbiology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntibacterial resistance
dc.subjectBee venom
dc.subjectCell culture
dc.subjectKlebsiella pneumoniae
dc.subjectNanovesicle fraction
dc.subjectAnimals
dc.subjectAnti-Bacterial Agents
dc.subjectBee Venoms
dc.subjectbeta-Lactamases
dc.subjectBiofilms
dc.subjectCell Line
dc.subjectHumans
dc.subjectKlebsiella Infections
dc.subjectMice
dc.subjectMicrobial Sensitivity Tests
dc.subjectantiinfective agent
dc.subjectbeta lactamase
dc.subjectanimal
dc.subjectbiofilm
dc.subjectchemistry
dc.subjectdrug effect
dc.subjectdrug therapy
dc.subjectenzymology
dc.subjectgenetics
dc.subjecthuman
dc.subjectKlebsiella infection
dc.subjectmetabolism
dc.subjectmicrobial sensitivity test
dc.subjectmicrobiology
dc.subjectmouse
dc.titleAlternative therapy against CTX-M broad spectrum β-lactamase resistance gene in Klebsiella pneumoniae infection: bee venom and bee venom-derived nanovesicle fraction
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentFaculty of Pharmacy, Department of Pharmaceutical Microbiology, Erzincan Binali Yıldırım University, Erzincan, 24002, Turkey. | Faculty of Medicine, Department of Medical Microbiology, Erzincan Binali Yıldırım University, Erzincan, 24002, Turkey.
rdl.oa.statusgreen
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)